Back

Roivant wins FDA approval for 30 mg LISRAYA in dermatomyositis

Verifying
  • Roivant Sciences secured FDA approval for LISRAYA to treat adults with dermatomyositis.
  • 55% of LISRAYA patients achieved moderate or better improvement with minimal or no steroids.
  • The Phase 3 VALOR trial tracked treatment progress through 52 weeks.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.